A Phase 3 Study of Rezpegaldesleukin (NKTR-358) for Patients ≥ 12 Years of Age With Moderate-to-Severe Atopic Dermatitis
Trial details
- Registry ID
- NCT07690371
- Drugs studied
- Rezpegaldesleukin
TrialRedline tracks 6 clinical trials sponsored by Nektar Therapeutics: 1 Phase 3, 1 Phase 2 / 3, 4 Phase 2.
Company identity checked against sources
| Trial | Drugs studied | Status | Primary completion |
|---|---|---|---|
| A Phase 3 Study of Rezpegaldesleukin (NKTR-358) for Patients ≥ 12 Years of Age With Moderate-to-Severe Atopic DermatitisNCT07690371 | Rezpegaldesleukin | Recruiting | 2028-05Estimated |
| Trial | Drugs studied | Status | Primary completion |
|---|---|---|---|
| NKTR-255 vs Placebo Following CD19-directed CAR-T Therapy in Patients With Relapsed/Refractory Large B-cell LymphomaNCT05664217 | NKTR-255 at 1.5 µg/kg, NKTR-255 at 3.0 μg/kg, NKTR-255 at 3.0/6.0 μg/kg | Terminated | 2024-05-22Actual |
| Trial | Drugs studied | Status | Primary completion |
|---|---|---|---|
| A Phase 2b Study to Evaluate Rezpegaldesleukin (Rezpeg) in the Treatment of Adult Patients With Moderate-to-Severe Atopic DermatitisNCT06136741 | Rezpegaldesleukin | Active not recruiting | 2025-05-06Actual |
| A Phase 2b Study to Evaluate Rezpegaldesleukin (Rezpeg) in the Treatment of Severe to Very Severe Alopecia Areata in Adult Patients (Rezolve AA)NCT06340360 | Rezpegaldesleukin | Completed | 2025-11-26Actual |
| A Study of LY3471851 in Adults With Systemic Lupus Erythematosus (SLE)NCT04433585 | LY3471851 | Completed | 2023-01-10Actual |
| A Study of LY3471851 in Adult Participants With Moderately to Severely Active Ulcerative Colitis (UC)NCT04677179 | LY3471851 | Terminated | 2022-08-09Actual |
Names as written in the registry records.
NCT05664217 · Nektar Therapeutics
Text changed; whether the study measures changed has not been verified. Saved text may be shortened.
Before: Measure: Complete response (CR) rate at month 6 Description: The incidence of complete response by the Lugano Classification (Cheson et al, 2014) as determined by blinded independent central review (BICR) Time frame: At month 6 after the first infusion with study drug Measure: Event-free survival (EFS) Description: Event-free survival is defined as the time from randomization to the earliest date of disease progression by the Lugano Classification (Cheson et al, 2014) as determined by BICR, commencement of new lymphoma therapy, or death from any cause. Time frame: Up to 3 years after the first infusion with study drug. After: Measure: Complete Response (CR) Rate Description: The incidence of complete response by the Lugano Classification (Cheson et al, 2014) as determined by blinded independent central review (BICR) Time frame: At month 6.
Before: Active not recruiting. After: Completed.
Before: Estimated. After: Actual.
Before: Nov 2025. After: 26 Nov 2025.